Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate

Athens, Greece — September 2, 2008 Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist…

Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on Alzheimer’s Disease 2008

Chicago, Illinois — July 30, 2008 — ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today presented data from the company’s novel compound, ANAVEX 1-41, targeting Alzheimer’s disease, at the International Conference on Alzheimer’s Disease (ICAD)…

Anavex Life Sciences Corp. Will Present New Findings at the International Conference on Alzheimer’s Disease 2008 (July 26-31, 2008, Chicago, USA)

Athens, Greece — June 24, 2008 — Anavex Life Sciences Corp.  (“ANAVEX”) (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer’s Disease 2008 (July 26–31, 2008,Chicago,USA), where it will present results obtained with ANAVEX 1-41 demonstrating a protective effect against the neurotoxicity of amyloid β25-35 peptide (Aβ25-35) in mice.  This peptide is used…

Anavex Announces Appointment of Oncology Specialist to Board of Directors

Athens, Greece — May 21, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTC BB:AVXL) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer (NYSE:PFE), with responsibility for Pfizer’s oncology portfolio, which includes more than 20 drug candidates in clinical development,…

ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity

Geneva, Switzerland — March 10, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that ANAVEX 7-1037 has demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.  The human tumor xenografts were developed in ANAVEX labs using a sample taken from a person suffering…

Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008

Geneva, Switzerland — January 22, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) reported today that the company achieved significant development of its lead drug candidates and in the growth of its management and scientific teams during 2007.  The company further disclosed key corporate objectives for 2008.“This past year has been extremely successful for…

Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease

Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits Geneva, Switzerland — November 28, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company’s lead drug candidate for Alzheimer’s disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress,…

Anavex Strengthens Board of Directors

Geneva, Switzerland — December 17, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced the appointment of Dr. Cameron Durrant to its Board of Directors. Dr. Durrant is currently Worldwide Vice President of Virology Global Strategic Marketing at Johnson & Johnson (NYSE: JNJ). “ANAVEX is both pleased and privileged to welcome Dr. Durrant…

ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors

Geneva, Switzerland — December 11, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies.  In addition, ANAVEX 7-1037 demonstrated its ability to significantly suppress tumor growth in immune-deficient mice.  ANAVEX 7-1037 is the company’s lead drug…